This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Esfahani K, Aspler A, Menzies D, Schwartzman K.Rifampin vs. isoniazid for treatment of latent tuberculosis: a cost-effectiveness analysis based on a multicenter clinical trial. 105th International Conference of the American Thoracic Society: 1018, 17 May 2009
Campbell JD, Spackman DE, Swensen A, Sullivan SD.Cost-effectiveness of omalizumab in moderate-to-severe asthma from the US payer perspective. 105th International Conference of the American Thoracic Society: 1411 abstr. D2, 17 May 2009
Dalal AA, Blanchette CM, Petersen H, St. Charles M.Cost-effectiveness of fluticasone propionate/salmeterol (250/50mcg) compared to salmeterol (50mcg) in patients with chronic obstructive pulmonary disease: economic evaluation of study SCO100250. 105th International Conference of the American Thoracic Society: 1502 abstr. K54, 17 May 2009
Effing TW, Kerstjens HAM, van der Valk PDLPM, Zielhuis GA, van der Palen J.The (cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in COPD patients: the COPE II-Study. 105th International Conference of the American Thoracic Society: 1535 abstr. K88, 17 May 2009
Woodward TC, Sacco P, Brown R.Budget impact model of adding toramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients. 105th International Conference of the American Thoracic Society: 1791 abstr. G40, 17 May 2009
Rights and permissions
About this article
Cite this article
Pharmacoeconomic news from ATS. Pharmacoecon. Outcomes News 580, 5 (2009). https://doi.org/10.2165/00151234-200905800-00012
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905800-00012